SEC Form 4 · accession 0001209191-18-062228
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gabriel Leung
Director
Period of report
Dec 10, 2017
Accepted (ET)
Dec 12, 2018 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Dec 10, 2018 | M | 5,000 | $3.44 | A | 65,000 | D | |
| Ordinary SharesF1 | Dec 10, 2018 | S | 5,000 | $33.49 | D | 60,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF2 | $3.44 | Dec 10, 2018 | M | 5,000 | A | — | Sep 14, 2021 | Ordinary Shares | 5,000 | 169,743 | D |
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung.
- F2Options to buy 5,000 ordinary shares are vested and currently exercisable as of the date hereof.